ARWR vs AZN
As of Sep 20, 2026, Arrowhead Pharmaceuticals (ARWR) scores 6.0/10 and Astrazeneca (AZN) 5.0/10 on AlphaStocks' five-model composite, so ARWR scores higher. AZN trades 14% below its model fair value.
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
6.0
Consider Buy
$66.56
AZN
ASTRAZENECA PLC
5.0
Consider Buy
$166.29
ARWR vs AZN: Which is the Better Investment?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) scores 6.0/10 while ASTRAZENECA PLC (AZN) scores 5.0/10 on AlphaStocks' composite model. ARROWHEAD PHARMACEUTICALS, INC. has the higher composite rating of Consider Buy.
This comparison is algorithmically generated and is not financial advice.
| Metric | ARWR | AZN |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 6.0/10▲ | 5.0/10 |
| Rating | Consider Buy▲ | Consider Buy |
| Price | $66.56 | $166.29 |
| P/E Ratio | — | 25.4 |
| ROE | -0.3% | 21.9%▲ |
| Market Cap | $9B | $260B |
| Fair Value | — | $192.63 |
| Dividend Yield | — | 1.9% |
| Sector Rank | #50 of 168▲ | #111 of 168 |
| Model Verdicts | ||
| Piotroski | Attractive | Strong▲ |
| Buffett | Neutral | Strong▲ |
| Graham | Neutral▲ | Caution |
| Lynch | Limited Data | Neutral▲ |
| Greenblatt | Caution | Neutral▲ |
Related comparisons
ARWR vs AZN: Which Stock Scores Higher?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) and ASTRAZENECA PLC (AZN) are both in the Health Care sector. ARWR currently leads with a composite score of 6.0/10 (Consider Buy) compared to AZN's 5.0/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer